Lead Product(s) : Potravitug
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Ysios Capital
Deal Size : $49.4 million
Deal Type : Series C Financing
Memo Therapeutics Increases Series C Financing to CHF 45 Million
Details : The new funding will bolster clinical advancement of MTx’s lead asset, AntiBKV, expanding the Phase II trial to become the largest BK viremia therapeutic study in kidney transplant recipients.
Product Name : AntiBKV
Product Type : Antibody
Upfront Cash : Undisclosed
July 05, 2024
Lead Product(s) : Potravitug
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Ysios Capital
Deal Size : $49.4 million
Deal Type : Series C Financing
Lead Product(s) : Artemether,Lumefantrine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis and Medicines for Malaria Venture Report Positive Data for Malaria in Babies
Details : Coartem® (artemether-lumefantrine) a novel formulation which is being developed forthe treatment of babies weighing less than 5kg with malaria.
Product Name : Coartem
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2024
Lead Product(s) : Artemether,Lumefantrine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Potravitug
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AntiBKV is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection.
Product Name : AntiBKV
Product Type : Antibody
Upfront Cash : Inapplicable
June 22, 2023
Lead Product(s) : Potravitug
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Potravitug
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AntiBKV is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. This infection can lead to loss of kidney function, as well as organ failure and rejection.
Product Name : AntiBKV
Product Type : Antibody
Upfront Cash : Inapplicable
February 05, 2023
Lead Product(s) : Potravitug
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Molecular Partners
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of MP0420/SKO136 (ensovibep), a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load r...
Product Name : MP0420
Product Type : Protein
Upfront Cash : Inapplicable
October 01, 2022
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Molecular Partners
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MP0420 (ensovibep) is a COVID-19 antiviral therapeutic candidate designed specifically to inactivate SARS-CoV-2 – the virus that causes COVID-19 – with extremely high potency that is preserved against novel variants.
Product Name : MP0420
Product Type : Protein
Upfront Cash : Inapplicable
April 23, 2022
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Details : Sublicences will allow manufacturers (Teva, Cipla, Biocon, Amneal, Viatris, Torrent, MSN, Sun Pharma, Cadila, Glenmark, Fosun, Beximco, Celltrion & others) to produce the raw materials for generic of Pfizer’s COVID-19 nirmatrelvir and finished drug co-...
Product Name : Nirmatrelvir-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 17, 2022
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In vitro data to-date demonstrate that ensovibep retains potency in inhibiting all known SARS-CoV-2 variants of concern, including the Delta variants. Ensovibep is the lead therapeutic candidate in Molecular Partners’ infectious disease pipeline.
Product Name : MP0420
Product Type : Protein
Upfront Cash : Inapplicable
November 16, 2021
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the results presented, neutralization assays demonstrate ensovibep’s ability to potently neutralize SARS-CoV-2 when testing the Wuhan or a reference strain.
Product Name : MP0420
Product Type : Protein
Upfront Cash : Inapplicable
October 20, 2021
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The objective of the current study is to determine whether RLF-100™, administered at the earlier (severe) stage of COVID-19 can reduce the likelihood of progression to critical COVID-19 with respiratory failure: the predominant cause of death in COVID-...
Product Name : Zyesami
Product Type : Peptide
Upfront Cash : Inapplicable
August 01, 2021
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable